AR057202A1 - Derivados de pirimidina para el tratamiento de crecimiento celular anormal - Google Patents

Derivados de pirimidina para el tratamiento de crecimiento celular anormal

Info

Publication number
AR057202A1
AR057202A1 ARP060105269A ARP060105269A AR057202A1 AR 057202 A1 AR057202 A1 AR 057202A1 AR P060105269 A ARP060105269 A AR P060105269A AR P060105269 A ARP060105269 A AR P060105269A AR 057202 A1 AR057202 A1 AR 057202A1
Authority
AR
Argentina
Prior art keywords
treatment
cellular growth
abnormal cellular
pirimidine derivatives
solvates
Prior art date
Application number
ARP060105269A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR057202A1 publication Critical patent/AR057202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP060105269A 2005-12-01 2006-11-29 Derivados de pirimidina para el tratamiento de crecimiento celular anormal AR057202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74125205P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
AR057202A1 true AR057202A1 (es) 2007-11-21

Family

ID=38092618

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105269A AR057202A1 (es) 2005-12-01 2006-11-29 Derivados de pirimidina para el tratamiento de crecimiento celular anormal

Country Status (7)

Country Link
US (1) US8722884B2 (https=)
EP (1) EP1966192B1 (https=)
JP (2) JP5134234B2 (https=)
AR (1) AR057202A1 (https=)
CA (1) CA2632149C (https=)
TW (1) TWI374880B (https=)
WO (1) WO2007063384A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
MX2010014057A (es) 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5937112B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ 選択的ｆａｋ阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5924990B2 (ja) * 1979-11-21 1984-06-13 協和醗酵工業株式会社 新規なピペリジン誘導体
GB9222700D0 (en) * 1992-10-29 1992-12-09 Smithkline Beecham Plc Chemical compounds
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
NZ502567A (en) * 1997-07-29 2002-03-28 Upjohn Co Self-emulsifying formulation for lipophilic compounds containing a pyranone and a mixture of monoglycerides and diglycerides
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
CA2465682A1 (en) * 2001-11-02 2003-05-08 Shire Biochem Inc. Methods of treating leukemia
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
OA13309A (en) 2002-12-20 2007-04-13 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013165A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) * 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.

Also Published As

Publication number Publication date
JP5134234B2 (ja) 2013-01-30
EP1966192B1 (en) 2012-10-17
WO2007063384A2 (en) 2007-06-07
CA2632149A1 (en) 2007-06-07
CA2632149C (en) 2011-11-15
JP2012255038A (ja) 2012-12-27
JP2007153892A (ja) 2007-06-21
EP1966192A2 (en) 2008-09-10
TW200730507A (en) 2007-08-16
TWI374880B (en) 2012-10-21
WO2007063384A3 (en) 2007-10-04
US20110033441A1 (en) 2011-02-10
US8722884B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
EA201170607A1 (ru) Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
CL2008002255A1 (es) Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf.
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
ATE530519T1 (de) Cyclobutylaminderivate
CO6270331A2 (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil -coenzima a desaturada
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
TW200942529A (en) Pyrrolidinyl derivatives and uses thereof
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NI200700316A (es) Aminopirimidinas como moduladores de la cinasa
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure